To Assess the Effectiveness of Three Distinct Mechanical Assisted Sputum Evacuation Apparatuses in the Treatment of Patients With Mechanical Ventilation-induced Atelectasis (EOTEOMASE)

Zhejiang University

Status: Not yet enrolling

Conditions: Atelectasis; Mechanical Ventilation

Treatments: Device: CVT; Device: MetaNeb; Device: HFCWO

Study type: Observational

Funder types: Other

Identifiers

NCT06631716

2024-2037-02

Details and patient eligibility

About

Retention of airway secretions is a common clinical problem in patients with mechanical ventilation. Effective removal of airway secretions requires a balance between the production and removal of airway secretions through the mucociliary transport system. Effective removal of airway secretions is the basic measure to maintain airway patency and normal alveolar ventilation and oxygenation. At present, a variety of mechanical assisted expectoration devices have been used to remove airway secretions in critically ill patients, including The MetaNeb® System(MetaNeb), High Frequency Chest Wall Oscillation(HFCWO) and (Cycloid Vibration Therapy)CVT. However, there is still a lack of sufficient evidence to evaluate the clinical efficacy of these three different mechanical assisted expectoration devices in airway management of patients with mechanical ventilation. This study aims to observe the clinical efficacy of three different mechanical assisted sputum evacuation devices in airway management of patients with mechanical ventilation atelectasis, and to provide a basis for optimizing the airway management scheme of patients with mechanical ventilation.

Enrollment: 84 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• ≥18 years old.
• patients who were diagnosed as obstructed airway secretion clearance and required mechanical sputum evacuation in Sir Run Run Shaw Hospital, Zhejiang University School of Medicine. Among them, patients using CVT were included in the CVT cohort, patients using Metaneb were included in the Metaneb cohort, and patients using high-frequency chest wall oscillation (HFCWO) were included in the high-frequency chest wall oscillation (HFCWO) cohort.
• voluntarily participated in this study and signed the informed consent. If the subjects were unable to read and sign the informed consent form due to incapacity or other reasons, their guardians were required to act for them during the informed consent process and sign the informed consent form. If the subjects were unable to read the informed consent form (e.g., illiterate subjects), witnesses were required to witness the informed consent process and sign the informed consent.
• Invasive mechanical ventilation ≥48 hours.
• Atelectasis was confirmed by chest CT, chest X-ray or lung ultrasound.

Exclusion criteria

• BMI≥40kg/m2.
• Severe spinal and thoracic deformity.
• Known or suspected diaphragmatic dysfunction such as phrenic nerve rupture, neuromuscular disease, etc.
• untreated tension pneumothorax.
• Active bleeding in the lung.
• Severe hemodynamic instability (increased dose of vasoactive drugs within 2 hours or MAP≤65mmHg).
• Severe other organ dysfunction was expected to result in short-term death (7 days) or palliative treatment.
• Other reasons considered by the medical team not suitable for treatment.
• Pregnancy status.